Related Experiment Video

Updated: Oct 7, 2025

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

6.9K

LncRNA HCG11 represses ovarian cancer cell growth via AKT signaling pathway

Xiaoping Chen1, Yusheng Yang2, Jie Sun3

  • 1Department of Gynecology and Obstetrics, Ningbo Yinzhou Second Hospital, Ningbo, Zhejiang, China.

The Journal of Obstetrics and Gynaecology Research
|January 11, 2022
PubMed
Abstract

Insights

HCG11 acts as a tumor suppressor in ovarian cancer, inhibiting cell growth and migration. This long non-coding RNA targets miR-1270 to upregulate PTEN, ultimately hindering the AKT/mTOR pathway for potential ovarian cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer is a leading cause of cancer deaths in women globally.
  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.
  • The tumor suppressor role of HCG11 is established in other cancers, but its function in ovarian cancer remains under-investigated.

Purpose of the Study:

  • To investigate the role of HCG11 in ovarian cancer.
  • To elucidate the molecular mechanism by which HCG11 affects ovarian cancer progression.
  • To explore the potential of HCG11 as a therapeutic target for ovarian cancer.

Main Methods:

  • Gene and protein expression analysis using RT-qPCR and western blot.
  • Functional assays to assess the impact of HCG11 on ovarian cancer cell behavior (proliferation, migration, EMT).
  • Bioinformatics and mechanistic experiments to determine the interaction between HCG11, miR-1270, and PTEN, and its effect on the AKT/mTOR pathway.

Main Results:

  • HCG11 expression is reduced in ovarian cancer tissues.
  • HCG11 functions as a tumor suppressor by inhibiting cell proliferation, migration, and epithelial-mesenchymal transition (EMT).
  • HCG11 directly binds to miR-1270, and PTEN is a target of miR-1270. HCG11 upregulates PTEN by competitively binding to miR-1270, thereby inhibiting the AKT/mTOR pathway and retarding ovarian cancer cell growth.

Conclusions:

  • HCG11 acts as a tumor suppressor in ovarian cancer.
  • HCG11 exerts its tumor-suppressive effects by modulating the miR-1270/PTEN axis, leading to the inhibition of the AKT/mTOR pathway.
  • HCG11 represents a potential therapeutic target for ovarian cancer treatment.
Keywords:
AKT pathwayHCG11PTENmiR-1270ovarian cancer

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K